Medication info

Acyclovir Injection 250 Milligrams (Acyclovir)

Prescription medicationIntravenous injection
Ingredient · strength
Acyclovir›250mg / 1 vial
Manufacturer / importer
Korea Chorus Co., Ltd.
Appearance
A colorless or light yellow transparent liquid in a colorless transparent vial.
Packaging
1 vial/box [10 milliliters/vial], 10 vials/box [10 milliliters/vial]
Approval status
Active

MFDS item code 202102424 · Notified 2021.03.18 · Insurance code 647205871

Summary

Main use
Treatment and prevention of herpes infections in immunocompromised patients; treatment of herpes infections and encephalitis in immunocompetent patients
Who receives it
Adults · Children
Adult administration
Each dose of the injection should be administered by slow intravenous infusion over at least 1 hour. The appropriate duration of treatment is 5 days, but it may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5mg/kg body weight every 8 hours. Recurrent varicella-zoster virus infections: In patients with normal immune function, administer this medicine 5mg/kg body weight every 8 hours. Initial and recurrent varicella-zoster virus infections: In immunocompromised patients, administer this medicine 10mg/kg body weight every 8 hours. Herpes simplex encephalitis: In patients with normal or impaired immune function, administer this medicine 10mg/kg body weight every 8 hours. Prevention of herpes simplex virus infections in immunocompromised patients: Consider this treatment when oral administration is not possible; determine the duration of treatment according to the period of risk of infection. In obese patients, intravenous administration of acyclovir based on actual body weight may increase plasma concentrations. Therefore, dose reduction should be considered in obese patients, particularly those with renal impairment or who are elderly. Use caution when administering this medicine to patients with renal impairment, as neuropsychiatric adverse reactions may occur more readily. The dosage is as follows. Creatinine clearance (mL/min) 25~50: Administer the recommended dose for the relevant indication above every 12 hours. Creatinine clearance (mL/min) 10~25: Administer the recommended dose for the relevant indication above every 24 hours. Creatinine clearance (mL/min) 0 (anuria)~10: Patients receiving peritoneal dialysis should receive half the recommended dose (2.5 or 5mg/kg body weight) every 24 hours. Patients receiving hemodialysis should receive half the recommended dose (2.5 or 5mg/kg body weight) every 24 hours and after dialysis.
Child administration
The dose for children (3 months~12 years) is calculated according to body surface area and administered as for adults. Children (3 months~12 years), herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infections: Administer 250mg per ㎡ of body surface area every 8 hours. Children (3 months~12 years), immunocompromised children with varicella-zoster infection or herpes simplex encephalitis: If renal function is normal, administer 500mg per ㎡ of body surface area every 8 hours. Adjust the dose appropriately according to the degree of impairment in pediatric patients with renal impairment.

Ingredients

Manufacturer
Korea Chorus Co., Ltd.

Efficacy & effects

Treatment and prevention of herpes infections in immunocompromised patients; treatment of herpes infections and encephalitis in immunocompetent patients

  • Severe primary genital herpes
  • recurrent varicella-zoster virus infections
  • herpes simplex encephalitis
  • herpes simplex virus infections
  • primary varicella-zoster virus infections.
View approved original text

This medication is used to treat severe primary genital herpes, recurrent varicella-zoster virus infection, and herpes simplex encephalitis in patients with normal immune function. It is also effective in treating and preventing herpes simplex virus infections, as well as treating primary and recurrent varicella-zoster virus infections and herpes simplex encephalitis in patients with impaired immune function. It is used for the treatment of various herpes simplex and varicella-zoster related viral infections.

How it is given

Adult administration

Each dose of the injection should be administered by slow intravenous infusion over at least 1 hour. The appropriate duration of treatment is 5 days, but it may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5mg/kg body weight every 8 hours. Recurrent varicella-zoster virus infections: In patients with normal immune function, administer this medicine 5mg/kg body weight every 8 hours. Initial and recurrent varicella-zoster virus infections: In immunocompromised patients, administer this medicine 10mg/kg body weight every 8 hours. Herpes simplex encephalitis: In patients with normal or impaired immune function, administer this medicine 10mg/kg body weight every 8 hours. Prevention of herpes simplex virus infections in immunocompromised patients: Consider this treatment when oral administration is not possible; determine the duration of treatment according to the period of risk of infection. In obese patients, intravenous administration of acyclovir based on actual body weight may increase plasma concentrations. Therefore, dose reduction should be considered in obese patients, particularly those with renal impairment or who are elderly. Use caution when administering this medicine to patients with renal impairment, as neuropsychiatric adverse reactions may occur more readily. The dosage is as follows. Creatinine clearance (mL/min) 25~50: Administer the recommended dose for the relevant indication above every 12 hours. Creatinine clearance (mL/min) 10~25: Administer the recommended dose for the relevant indication above every 24 hours. Creatinine clearance (mL/min) 0 (anuria)~10: Patients receiving peritoneal dialysis should receive half the recommended dose (2.5 or 5mg/kg body weight) every 24 hours. Patients receiving hemodialysis should receive half the recommended dose (2.5 or 5mg/kg body weight) every 24 hours and after dialysis.

Child administration

The dose for children (3 months~12 years) is calculated according to body surface area and administered as for adults. Children (3 months~12 years), herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infections: Administer 250mg per ㎡ of body surface area every 8 hours. Children (3 months~12 years), immunocompromised children with varicella-zoster infection or herpes simplex encephalitis: If renal function is normal, administer 500mg per ㎡ of body surface area every 8 hours. Adjust the dose appropriately according to the degree of impairment in pediatric patients with renal impairment.

Precautions

This medication should not be used in patients who have had an allergic reaction to this medication, its components, or valacyclovir. Patients with impaired renal function should use with caution as neuropsychiatric adverse reactions may occur. Patients with poor liver function should use this medication carefully as it may worsen liver function. It should be used with special caution in infants, children, and the elderly. While using this medication, a severe allergic reaction known as anaphylactic shock may rarely occur, so if symptoms such as hypotension, dyspnea, or chest tightness appear, stop using the medication immediately and seek appropriate treatment. Hypersensitivity reactions such as rash, fever, vesicles, urticaria may occur; if these symptoms arise, stop the medication and consult a doctor. Skin-related side effects may include hair loss, erythema multiforme, severe skin conditions such as Stevens-Johnson syndrome or toxic epidermal necrolysis. Neuropsychiatric side effects may include altered consciousness, hallucinations, seizures, anxiety, dizziness, confusion, numbness, tremors, drowsiness, headaches, and fatigue. Kidney problems may lead to acute renal failure, hematuria, proteinuria, and if any issues occur, the dosage should be adjusted or administration should be stopped. Liver effects can lead to hepatitis, jaundice, and elevated liver function test values; if any symptoms of liver dysfunction occur, discontinue the medication. Hematologic side effects can include bleeding, changes in white blood cell or platelet counts, and anemia. Gastrointestinal side effects may include gastritis, dyspepsia, nausea, vomiting, abdominal pain, diarrhea, and loss of appetite. Cardiovascular side effects may include chest pain, palpitations, arrhythmias, and changes in blood pressure. Muscle pain or joint pain may also occur. Urological effects may include dysuria or urinary obstruction. General side effects may include edema, syncope, muscle weakness, fever, headaches, pallor, and feeling cold. Other reported side effects include pneumonia, laryngitis, visual disturbances, taste disorders, hair loss, sweating, and electrolyte abnormalities. When administering the medication, it is effective to start as soon as possible, especially at high doses where adequate hydration is necessary to prevent dehydration and reduce the risk of renal toxicity. This medication may interact with other drugs, so caution should be taken when used concurrently with medications such as probenecid, cimetidine, mycophenolate mofetil, and theophylline. During pregnancy, this should only be used when absolutely necessary, as it may affect the fetus; during breastfeeding, it should be discontinued as the drug may be excreted in breast milk. In infants and children, it should be administered cautiously only when necessary, and in the elderly, dosage adjustment may be required due to increased drug concentration resulting from reduced renal function. In cases of overdose, symptoms may include agitation, coma, seizures, drowsiness, and renal function may worsen, therefore immediate medical advice should be sought and if necessary, treatment such as hemodialysis should be provided. This drug should be administered slowly through a drip infusion rather than by rapid intravenous injection. Care should be taken to prevent extravasation at the injection site. Before use, the solution should be well shaken, and if precipitation occurs upon dilution, it should not be used. Mixing with other drugs should be avoided as it is alkaline, and changes in pH can easily lead to incompatibility.

Side effects

  • Anaphylactic shock
  • anaphylactic reaction
  • hypotension
  • dyspnea
  • chest tightness
  • rash
  • fever
  • vesicles
  • urticarial erythema
  • urticaria
Show 114 more
  • photosensitivity reaction
  • fixed drug eruption
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • delirium
  • convulsions
  • anxiety
  • speech impairment
  • dizziness
  • hallucinations
  • loss of directional sense
  • confusion
  • paresthesia of the limbs
  • numbness of the tongue and extremities
  • tremors
  • drowsiness
  • headache
  • generalized malaise
  • mood swings
  • emotional instability
  • concentration disorders
  • depersonalization
  • forgetfulness
  • insomnia
  • ataxia
  • talking to oneself
  • abnormal sensations
  • gait abnormalities
  • involuntary movements
  • acute renal failure
  • pyuria
  • crystalluria
  • elevated BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • urinary erythrocyte casts
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hemorrhage
  • leukocytosis
  • eosinophilia
  • lymphocytopenia
  • thrombocytosis
  • agranulocytosis
  • anemia
  • purpura
  • thrombocytopenia
  • neutropenia
  • eosinophilia
  • lymphocytosis
  • disseminated intravascular coagulation
  • gastritis
  • dyspepsia
  • glossitis
  • dry mouth
  • constipation
  • acute pancreatitis
  • nausea
  • vomiting
  • abdominal pain
  • gastric pain
  • epigastric pain
  • gastric discomfort
  • diarrhea
  • loose stools
  • loss of appetite
  • chest pain
  • palpitations
  • tachycardia
  • increased blood pressure
  • arrhythmia
  • decreased blood pressure
  • arthralgia
  • myalgia
  • dysuria
  • urinary obstruction
  • edema
  • syncope
  • decreased muscle strength
  • fever
  • pallor
  • chill
  • pneumonia
  • laryngitis
  • pleural effusion
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • sweating
  • hyponatremia
  • decreased serum albumin level
  • decreased serum potassium level
  • decreased blood protein levels
  • elevated cholesterol levels
  • elevated triglyceride levels
  • dyspnea
  • feeling of chest heaviness
  • glucosuria
  • ulcers
  • agitation
  • coma
  • confusion
  • excitement
  • epilepsy
  • comatose state
  • pain at the injection site
  • sudden vascular weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to prevent air and moisture ingress and kept at a cool temperature below 25 degrees Celsius. Storing it this way helps maintain the drug's efficacy for a long time.

Appearance and packaging

Appearance

A colorless or light yellow transparent liquid in a colorless transparent vial.

Package unit

1 vial/box [10 milliliters/vial], 10 vials/box [10 milliliters/vial]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.